How the progression of disability is measured in Multiple Sclerosis

Drafting MSP

January 12, 2022

# Scientific MSPC | The drug OCREVUS reduced relapses and delayed the progression of disability in relapsing multiple sclerosis, as evidenced in several studies, where this drug was compared with REBIF.

Participants in the studies with relapsed MS fared better with this treatment.

#MSP: The most relevant for doctors, patients and health professionals. #Pioneers

#UnProductoOriginal

#NoAlPlagio

Share:

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

On Key

Related Posts